Alnylam Pharmaceuticals income from continuous operations for the twelve months ending September 30, 2024 was $-0.332B, a 34.83% decline year-over-year.
Alnylam Pharmaceuticals annual income from continuous operations for 2023 was $-0.44B, a 61.08% decline from 2022.
Alnylam Pharmaceuticals annual income from continuous operations for 2022 was $-1.131B, a 32.64% increase from 2021.
Alnylam Pharmaceuticals annual income from continuous operations for 2021 was $-0.853B, a 0.64% decline from 2020.
Alnylam Pharmaceuticals Income from Continuous Operations 2010-2024 | ALNY